New eye drops aim to soothe dry eye sufferers

NCT ID NCT06424444

Completed Symptom relief Sponsor: Aldeyra Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tested whether reproxalap eye drops can safely reduce discomfort in people with dry eye disease. 421 adults used the drops or a placebo for up to 6 weeks. The main goal was to measure changes in eye discomfort scores over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: reproxalap ophthalmic solution (0.25%)
What this could lead to: If successful, this could provide a new eye drop option to reduce discomfort in people with dry eye disease.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. The improvement over placebo may be small, and long-term safety is not fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRY EYE DISEASE

Contacts and locations

Locations

Core, Inc.

Shelby, North Carolina, 28150, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.